$PCSA
Processa Pharmaceuticals, Inc. Stock $pcsa

$pcsa Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223009730 Filed on March 30, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.478M	$2.625M	$8.763M
YoY Change	21.24%	102.29%	86.89%
% of Gross Profit
Research & Development	$1.627M	$2.977M	$11.49M
YoY Change	64.79%	58.86%	88.82%
% of Gross Profit
Depreciation & Amortization	$0.00	$197.1K	$0.00
YoY Change		0.01%	-100.0%
% of Gross Profit
Operating Expenses	$1.627M	$5.800M	$11.49M
YoY Change	-49.59%	72.15%	-0.63%
Operating Profit	-$4.106M		-$27.53M
YoY Change	27.16%		126.85%
Interest Expense		$55.53K	$101.2K
YoY Change		1504.91%	770.16%
% of Operating Profit
Other Income/Expense, Net	$83.46K
YoY Change	5172.39%
Pretax Income	-$4.022M	-$13.01M	-$27.42M
YoY Change	24.63%	286.63%	129.34%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$4.022M	-$13.01M	-$27.42M
YoY Change	24.63%	308.71%	139.98%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.18		-$1.70
Diluted Earnings Per Share	-$0.18	-$0.79	-$1.70
COMMON SHARES
Basic Shares Outstanding	24.56M shares	15.99M shares	16.11M shares
Diluted Shares Outstanding	1.139M shares		805.5K shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.74M	$6.504M	$6.504M
YoY Change	-25.38%	-60.58%	-60.58%
Cash & Equivalents	$10.74M	$6.504M	$6.504M
Short-Term Investments
Other Short-Term Assets	$1.478M	$1.883M	$1.883M
YoY Change	-25.73%	7.04%	7.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$12.22M	$8.387M	$8.387M
YoY Change	-25.42%	-54.24%	-54.24%
LONG-TERM ASSETS
Property, Plant & Equipment		$227.6K	$227.6K
YoY Change			206.81%
Goodwill
YoY Change
Intangibles		$0.00
YoY Change		-100.0%
Long-Term Investments
YoY Change
Other Assets	$213.3K	$5.535K	$5.540K
YoY Change	3750.58%	-99.93%	0.0%
Total Long-Term Assets	$213.3K	$233.1K	$233.1K
YoY Change	-97.31%	-97.13%	-97.13%
TOTAL ASSETS
Total Short-Term Assets	$12.22M	$8.387M	$8.387M
Total Long-Term Assets	$213.3K	$233.1K	$233.1K
Total Assets	$12.43M	$8.620M	$8.620M
YoY Change	-48.84%	-67.43%	-67.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$316.7K	$327.5K	$327.6K
YoY Change	0.2%	49.63%	49.63%
Accrued Expenses	$1.574M	$403.1K	$482.0K
YoY Change	360.64%	44.33%	37.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.161M	$998.6K	$998.6K
YoY Change	104.28%	2.84%	2.84%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$129.4K	$150.6K	$150.6K
YoY Change	2003.41%	1937.21%	1937.21%
Total Long-Term Liabilities	$129.4K	$150.6K	$150.6K
YoY Change	2003.41%	1937.21%	1937.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.161M	$998.6K	$998.6K
Total Long-Term Liabilities	$129.4K	$150.6K	$150.6K
Total Liabilities	$2.290M	$1.149M	$1.149M
YoY Change	115.26%	17.45%	17.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$68.30M	-$64.20M
YoY Change		74.35%
Common Stock	$78.71M	$72.02M
YoY Change		15.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$300.0K	$300.0K
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.14M	$7.471M	$7.471M
YoY Change
Total Liabilities & Shareholders Equity	$12.43M	$8.620M	$8.620M
YoY Change	-48.84%	-67.43%	-67.43%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$4.022M	-$13.01M	-$27.42M
YoY Change	24.63%	308.71%	139.98%
Depreciation, Depletion And Amortization	$0.00	$197.1K	$0.00
YoY Change		0.01%	-100.0%
Cash From Operating Activities	-$2.114M	-$2.497M	-$9.600M
YoY Change	17.26%	-8.42%	10.13%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$6.400M
YoY Change			-36.32%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$6.352M	-53.59K	-$388.8K
YoY Change	-2217.36%	-140.8%	-103.97%
NET CHANGE
Cash From Operating Activities	-$2.114M	-2.497M	-$9.600M
Cash From Investing Activities
Cash From Financing Activities	$6.352M	-53.59K	-$388.8K
Net Change In Cash	$4.238M	-2.551M	-$9.994M
YoY Change	-301.53%	-1.72%	-1024.21%
FREE CASH FLOW
Cash From Operating Activities	-$2.114M	-$2.497M	-$9.600M
Capital Expenditures
Free Cash Flow			-$9.600M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001533743
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	PCSA	Due From Tax Agencies DueFromTaxAgencies		usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess		usd
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2022	PCSA	Forgiveness Of Payroll Protection Program Loan And Related Accrued Interest ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Depreciation Depreciation		usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense		usd
CY2022	PCSA	Non Cash Acquisition Of Inprocess Research And Development NonCashAcquisitionOfInprocessResearchAndDevelopment		usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	PCSA	Forgiveness Of Payroll Protection Program Loan And Related Accrued Interest ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest		usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2021	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity		usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	PCSA	Stock Issued In Satisfaction Of Accrued Expense StockIssuedInSatisfactionOfAccruedExpense		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	PCSA	Non Cashlease Liability Net NonCashleaseLiabilityNet		usd
CY2021	PCSA	Non Cashlease Liability Net NonCashleaseLiabilityNet		usd
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2021Q4	PCSA	Impairment Of Intangible Asset ImpairmentOfIntangibleAsset		usd
CY2022	dei	Auditor Firm AuditorFirmId	6143
CY2022	dei	Auditor Location AuditorLocation	Owings Mills, MD
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6503595	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16497581	usd
CY2021Q4	PCSA	Due From Tax Agencies DueFromTaxAgencies	70274	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1883134	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1759296	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8386729	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	18327151	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	227587	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	74181	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	PCSA	Net Deferred Tax Benefit NetDeferredTaxBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q4	PCSA	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts		usd
CY2022Q4	PCSA	Deferred Tax Assets Startup Expenditures DeferredTaxAssetsStartupExpenditures		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets		usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39531
CY2022	dei	Entity Registrant Name EntityRegistrantName	Processa Pharmaceuticals, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-1539785
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	7380 Coca Cola Drive
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 106
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Hanover
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	21076
CY2022	dei	City Area Code CityAreaCode	(443)
CY2022	dei	Local Phone Number LocalPhoneNumber	776-3133
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	PCSA
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	33800000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24557592	shares
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8056638	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5535	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5535	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	233122	usd
CY2021	PCSA	Forgiveness Of Payroll Protection Program Loan And Related Accrued Interest ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest	163771	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	101202	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	11627	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27424229	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11958145	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	8136354	usd
CY2022Q4	us-gaap	Assets Assets	8619851	usd
CY2021Q4	us-gaap	Assets Assets	26463505	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	78896	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	71078	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	327548	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	218905	usd
CY2022Q4	PCSA	Due To Licensor DueToLicensor	189000	usd
CY2021Q4	PCSA	Due To Licensor DueToLicensor	400000	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	51	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1772	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	403061	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	279265	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	998556	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	971020	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	150554	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7385	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1149110	usd
CY2021Q4	us-gaap	Liabilities Liabilities	978405	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16135400	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16035400	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15710246	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15710246	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1614	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1571	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	72016688	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	62306861	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	300000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64247561	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36823332	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7470741	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	25485100	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8619851	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26463505	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11494230	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6878021	usd
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	566583	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8763058	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4688939	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	7268143	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-27525431	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-12133543	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-530611	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-27424229	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-11427534	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.70
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16109291	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15319463	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16109291	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15319463	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	22939478	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3288015	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9875550	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	700000	usd
CY2021	PCSA	Shares Withheld To Pay Income Tax On Stockbased Compensation SharesWithheldToPayIncomeTaxOnStockbasedCompensation	64396	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	173987	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-11427534	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	25485100	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	300000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8948713	usd
CY2022	PCSA	Shares Issued In Connection With Purchase Agreement Value SharesIssuedInConnectionWithPurchaseAgreementValue	450000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	400000	usd
CY2022	PCSA	Shares Withheld To Pay Income Tax On Stockbased Compensation SharesWithheldToPayIncomeTaxOnStockbasedCompensation	88843	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-27424229	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7470741	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-27424229	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-11427534	usd
CY2021	us-gaap	Depreciation Depreciation	484	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	85518	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	84377	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-189000	usd
CY2021	PCSA	Non Cash Acquisition Of Inprocess Research And Development NonCashAcquisitionOfInprocessResearchAndDevelopment	300000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	115613	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	788495	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	790488	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	7268143	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-530611	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	8828713	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	3408015	usd
CY2021	PCSA	Forgiveness Of Payroll Protection Program Loan And Related Accrued Interest ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest	163771	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-210549	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1018095	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-87937	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-87200	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	108643	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-101789	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-1721	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	86644	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-70274	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-6750	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	243796	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-65049	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9605143	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8717291	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10049537	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	88843	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	64396	usd
CY2022	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	300000	usd
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-186493	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-388843	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9798648	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9993986	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1081357	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16497581	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15416224	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6503595	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16497581	usd
CY2022	PCSA	Stock Issued In Satisfaction Of Accrued Expense StockIssuedInSatisfactionOfAccruedExpense	120000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	450000	usd
CY2022	PCSA	Stock Issued In Connection With Licensing Agreement Which Had Previously Been Recorded As Due To Licensor StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor	400000	usd
CY2021	PCSA	Stock Issued In Connection With Licensing Agreement Which Had Previously Been Recorded As Due To Licensor StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor	400000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	238924	usd
CY2022	PCSA	Operating Lease Liabilities OperatingLeaseLiabilities	238924	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64200000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-27400000	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	17400000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9600000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6400000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zqLl48LHOFP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use of Estimates</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing our consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used for, but not limited to: stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	7300000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2577910	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	822430	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2600000	shares
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11059429	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3791286	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3002791	usd
CY2022Q4	PCSA	Impairment Of Intangible Asset ImpairmentOfIntangibleAsset	-7268143	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11494230	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6878021	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	7400000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11059429	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8056638	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	788495	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	790488	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	7300000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	24000000.0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	12500000	usd
CY2022	PCSA	Net Operating Loss Carryforward Expiry Date NetOperatingLossCarryforwardExpiryDate	2037
CY2022	PCSA	Net Operating Loss Carryforward Term NetOperatingLossCarryforwardTerm	P20Y
CY2022	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	Pursuant to Code Sec. 382 of the Internal Revenue Code (“the Code”), the utilization of our net operating loss carryforwards could be limited as a result of a cumulative change in stock ownership of more than 50% over a three-year period. We have not completed a Sec. 382 study and as such our net operating loss carryforwards may be subject to such limitation.
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-5887151	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2853937	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1567560	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-624844	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-7454711	usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-3478781	usd
CY2022	PCSA	Valuation Allowance Deferred Tax ValuationAllowanceDeferredTax	-7454711	usd
CY2021	PCSA	Valuation Allowance Deferred Tax ValuationAllowanceDeferredTax	-2948170	usd
CY2021	PCSA	Net Deferred Tax Benefit NetDeferredTaxBenefit	-530611	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-530611	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-530611	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0572	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0523	pure
CY2022	PCSA	Effective Income Tax Rate Reconciliation Income Tax Rate Permanent Differential EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential	-0.0055	pure
CY2021	PCSA	Effective Income Tax Rate Reconciliation Income Tax Rate Permanent Differential EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential	-0.0018	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0093	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0304	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2710	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2465	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0444	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	5048175	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	2615518	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	1431839	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	760897	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2590890	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	593365	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	976	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	13200	usd
CY2022Q4	PCSA	Deferred Tax Asset Acquired Inprocess Research And Development Tax Effected DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected	2494829	usd
CY2021Q4	PCSA	Deferred Tax Asset Acquired Inprocess Research And Development Tax Effected DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected	2481070	usd
CY2022Q4	PCSA	Deferred Tax Assets Federal Orphan Drug Credits DeferredTaxAssetsFederalOrphanDrugCredits	1046539	usd
CY2021Q4	PCSA	Deferred Tax Assets Federal Orphan Drug Credits DeferredTaxAssetsFederalOrphanDrugCredits	791151	usd
CY2022Q4	PCSA	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	1929462	usd
CY2021Q4	PCSA	Deferred Tax Assets Startup Expenditures DeferredTaxAssetsStartupExpenditures	1978418	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14542710	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9233619	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14542710	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7087999	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2145620	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2145620	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2145620	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	7400000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7400000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2900000	usd
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	8828713	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	3408015	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0185	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8177	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	152806	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.11
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	30000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.70
CY2021	PCSA	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2	P1Y2M12D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	4310	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.80
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	178496	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.07
CY2021	PCSA	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P3Y7M6D
CY2022Q4	PCSA	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber	178496	shares
CY2022Q4	PCSA	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice	17.07
CY2022	PCSA	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding And Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageRemainingContractualTerm	P2Y7M6D
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-27424229	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-11427534	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16109291	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15319463	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.70
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2577910	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	822430	shares
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2022	us-gaap	Lease Cost LeaseCost	96785	usd
CY2021	us-gaap	Lease Cost LeaseCost	94263	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	93845	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	92356	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	70040	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	256241	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	26791	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	229450	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	78896	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	150554	usd
CY2022	dei	Auditor Name AuditorName	BD & Company, Inc

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
pcsa-20221231_cal.xml	Edgar Link	unprocessable
pcsa-20221231_pre.xml	Edgar Link	unprocessable
0001493152-23-009730-index-headers.html	Edgar Link	pending
0001493152-23-009730-index.html	Edgar Link	pending
0001493152-23-009730.txt	Edgar Link	pending
0001493152-23-009730-xbrl.zip	Edgar Link	pending
ex10-13.htm	Edgar Link	pending
ex10-13_001.jpg	Edgar Link	pending
ex10-13_002.jpg	Edgar Link	pending
ex10-13_003.jpg	Edgar Link	pending
ex10-13_004.jpg	Edgar Link	pending
ex10-13_005.jpg	Edgar Link	pending
ex10-13_006.jpg	Edgar Link	pending
ex10-13_007.jpg	Edgar Link	pending
ex10-13_008.jpg	Edgar Link	pending
ex10-13_009.jpg	Edgar Link	pending
ex10-13_010.jpg	Edgar Link	pending
ex10-13_011.jpg	Edgar Link	pending
ex10-13_012.jpg	Edgar Link	pending
ex10-13_013.jpg	Edgar Link	pending
ex10-13_014.jpg	Edgar Link	pending
ex10-13_015.jpg	Edgar Link	pending
ex10-13_016.jpg	Edgar Link	pending
ex10-13_017.jpg	Edgar Link	pending
ex10-13_018.jpg	Edgar Link	pending
ex10-13_019.jpg	Edgar Link	pending
ex10-13_020.jpg	Edgar Link	pending
ex10-13_021.jpg	Edgar Link	pending
ex10-13_022.jpg	Edgar Link	pending
ex10-13_023.jpg	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
logo_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pcsa-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
pcsa-20221231_def.xml	Edgar Link	unprocessable
pcsa-20221231_lab.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCSA
Processa Pharmaceuticals, Inc. Stock $pcsa

2023 Q1 Form 10-K Financial Statement

#000149315223009730 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCSA Processa Pharmaceuticals, Inc. Stock $pcsa

2023 Q1 Form 10-K Financial Statement

#000149315223009730 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCSA
Processa Pharmaceuticals, Inc. Stock $pcsa